sierra: I agree that patents and copyrights are not big issues or concerns in China, as I've read and heard. I do think though that there are many parts to this problem: 1) BioShield Technologies, Inc., may be suffering from previous bad press (deserved or not) and a change may rejuvenate that; 2)investors have to be tired of the many apparent unfulfilled promises that have been made in the PRs, 3) attempts to create new companies when the parent and now the siblings are performing below par as its eMed did in the past (kinda like father like son); 4) marketing may not be as focused as it could be and the consultants may not be consulting on the right things: For example, I just heard that an insurance company, a reputable insurance firm catering to military retirees will stop issuing home insurance because of mildew and mold problems losses. Would it not be a great place for BSTI to look or if it has already looked for it to expedite business opportunities with its prospective customers? Has it communicated with insurance companies to get their conception of what it would take for them to continue offering the insurance at reasonable rates if they are to offer home insurance at all? Is there a way to use BSTI products to mildew/mold proof a house? 5) is management assessing contributions of consultants or is it simply paying for empty consulting services that have no useful purpose? 6) is it optimizing its research opportunities from Federal and State sources under various Small Business Innovative Research (I've written on this before)? I have since learned that a publically traded company is eligible for consideration if its stock is at least 51% publically owned by US Citizens or foreign persons lawfully admitted for permanent residence. This is free money, in the thousands, for BSTI to research ideas and development of those ideas. BSTI is not now doing sufficient research to enhance its products or to keep some research going at all times. Government money is where most of the pharmaceutical companies get their research money (not SBIRs but government sources) and they then get to charge a small fortune for cost of research that they never paid for in the first place. I think that BSTI should recruit from among its investors to go to Atlanta for a brief and brainstorming session on how BSTI could be improved and perhaps authorize knowledgeable investors to approach and present ideas to potential customers (pass on interest back to Tim). My first recommendation is that the name BioShield Technologies, Inc., be retired and a new name be adopted. I've read too many negative things about the company in the investment communities boards to think that this negativism can be overcome. ONLY a huge deal will bring it about and although there appears to be promise in the recent EPA approvals for new uses, it is precisely the negative connotation from previous times that is keeping Tim from cementing good contracts.
E
Market Data 
Markets 
AI
